Heidi Barth, Eric Robinet, T. Jake Liang, Thomas F. Baumert 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Laurent Mailly, Mirjam B. Zeisel, Thomas F. Baumert 
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Inflammasomes in liver diseases
Volume 65, Issue 1, Pages S2-S21 (October 2016)
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
R. Cavallo  Clinical Microbiology and Infection 
Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials  Pippa Newell, Augusto Villanueva, Josep M. Llovet 
Volume 68, Issue 5, Pages (May 2018)
Mirjam B. Zeisel, Isabel Fofana, Samira Fafi-Kremer, Thomas F. Baumert 
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 44, Issue 4, Pages (April 2006)
NS5A inhibitors in the treatment of hepatitis C
Stem cell therapies for liver failure and cirrhosis
Immigration and viral hepatitis
Is HCV Infection a Neurologic Disorder?
Volume 66, Issue 1, Pages 1-4 (January 2017)
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Hepatitis C virus entry and glucocorticosteroids
Living donor liver transplantation: is the hype over?
Thomas F. Baumert, Catherine Fauvelle, Diana Y. Chen, Georg M. Lauer 
Mesenchymal stromal cell therapy for liver diseases
Reply to: “DCD consensus and futility in liver transplantation”
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Volume 37, Issue 4, Pages (October 2002)
Jordan J. Feld, Graham R. Foster  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Burcin Ekser, Eric Lagasse  Journal of Hepatology 
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
RNAi – A powerful tool to unravel hepatitis C virus–host interactions within the infectious life cycle  Joachim Lupberger, Laurent Brino, Thomas F. Baumert 
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Liver is liver and blood is blood, and finally the twain have met
Ribavirin ante portas: Uptake transporters into hepatocytes dissected
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Advancing hepatitis B virus entry inhibitors
Volume 43, Issue 4, Pages (October 2005)
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
Host-targeting agents for prevention and treatment of chronic hepatitis C – Perspectives and challenges  Mirjam B. Zeisel, Joachim Lupberger, Isabel Fofana,
Severe Constipation Clinical Gastroenterology and Hepatology
EASL Clinical Practice Guidelines: Wilson’s disease
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Volume 65, Issue 2, Pages (August 2016)
Volume 50, Issue 4, Pages (April 2009)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
miR-122 – A key factor and therapeutic target in liver disease
Volume 56, Issue 6, Pages (June 2012)
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
Volume 63, Issue 1, Pages (July 2015)
Serum HBV pgRNA as a clinical marker for cccDNA activity
Volume 51, Issue 2, Pages (August 2009)
HCV animal models and liver disease
Liver transplantation in children
Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi 
Pathogenesis of cholestatic hepatitis C
Table of contents The Journal for Nurse Practitioners
Chimeric mouse model of hepatitis B virus infection
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Mirjam B. Zeisel, Marine Turek, Thomas F. Baumert 
Volume 64, Issue 6, Pages (June 2016)
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Mouse models for the study of HCV infection and virus–host interactions  Heidi Barth, Eric Robinet, T. Jake Liang, Thomas F. Baumert  Journal of Hepatology  Volume 49, Issue 1, Pages 134-142 (July 2008) DOI: 10.1016/j.jhep.2008.03.012 Copyright © 2008 Terms and Conditions

Fig. 1 Chimeric transgenic mice repopulated with human hepatocytes for the study of HCV infection. Hemizygous Alb-uPA mice were crossed to homozygosity with homozygous SCID/bg mice. The resulting Alb-uPA/SCID mice can be transplanted with human hepatocytes and support HCV infection from human infected-serum or recombinant cell culture-derived HCV (HCVcc). This model has been successfully used to study virus–host interactions in infected hepatocytes as well as the evaluation of antiviral strategies including antiviral drugs and monoclonal antibodies. The evaluation of cell therapy products may represent another application of this model in the future. Journal of Hepatology 2008 49, 134-142DOI: (10.1016/j.jhep.2008.03.012) Copyright © 2008 Terms and Conditions